Sanofi sees 'strong strategic' fit with U.S. Medivation
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- SanDisk stock rallies on AI optimism and Fed relief
Leerink Partners Raises Price Target on Regeneron (REGN) Following 1Q Report
May 6, 2016 9:08 AM EDTLeerink Partners reiterated an Outperform rating on Regeneron Pharma (NASDAQ: REGN), and raised the price target to $530.00 (from $523.00), following the company's 1Q earnings report. Total revenue beat consensus by 2% driven by higher collaboration revenue, and revenue grew by 38% compared to Q1 2015 and by 9% QoQ. The companys earnings fell short of consensus based on higher than expected SG&A and taxes. Pro forma EPS was $2.57 below consensus of $2.68.
Analyst Geoffrey Porges... More
Baird Cuts Price Target on Regeneron (REGN) to $505; Reiterates Outperform
May 5, 2016 3:25 PM EDTBaird maintained an Outperform rating on Regeneron Pharma (NASDAQ: REGN), and cut the price target to $505.00 (from $526.00), following the company's 1Q earnings report. EPS of $2.57 was reported in-line with expectations. Baird continues to believe that the copmant can deliver growth over the next few... More
